Less invasive HeartMate 3 left ventricular assist device implantation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F18%3A00076945" target="_blank" >RIV/00023001:_____/18:00076945 - isvavai.cz</a>

Výsledek na webu

<a href="http://jtd.amegroups.com/article/view/19930/html" target="_blank" >http://jtd.amegroups.com/article/view/19930/html</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21037/jtd.2018.01.26" target="_blank" >10.21037/jtd.2018.01.26</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Less invasive HeartMate 3 left ventricular assist device implantation

Popis výsledku v původním jazyce

Background: The novel HeartMate 3 (Abbott, Chicago, IL, USA) left ventricular assist device (LVAD) was worldwide first implanted by Prof. Schmitto and his team in 2014 at the Hannover Medical School, Germany and received CE Mark approval in October, 2015 following completion of a clinical trial. Methods: Although HeartMate 3 implantation in the clinical trial was restricted to conventional sternotomy, the small size of the pump allows for less-invasive implantation, generally associated with less trauma and reduced perioperative complication rates. Herein we describe our first experiences with a less-invasive implantation of the HeartMate 3 using an upper hemi-sternotomy combined with anterior lateral thoracotomy approach. Results: Results demonstrate the feasibility of this novel, less invasive technique for HeartMate 3 LVAD implantation with diminished surgical trauma, less postoperative bleeding, maintenance of the chest stability, reduced need of blood product transfusion and earlier recovery. Conclusions: The results of our study indicate that less-invasive implantation of the HeartMate 3 is technically feasible and offers several benefits for surgical outcome and may become the standard of care for LVAD implantation techniques.

Název v anglickém jazyce

Less invasive HeartMate 3 left ventricular assist device implantation

Popis výsledku anglicky

Background: The novel HeartMate 3 (Abbott, Chicago, IL, USA) left ventricular assist device (LVAD) was worldwide first implanted by Prof. Schmitto and his team in 2014 at the Hannover Medical School, Germany and received CE Mark approval in October, 2015 following completion of a clinical trial. Methods: Although HeartMate 3 implantation in the clinical trial was restricted to conventional sternotomy, the small size of the pump allows for less-invasive implantation, generally associated with less trauma and reduced perioperative complication rates. Herein we describe our first experiences with a less-invasive implantation of the HeartMate 3 using an upper hemi-sternotomy combined with anterior lateral thoracotomy approach. Results: Results demonstrate the feasibility of this novel, less invasive technique for HeartMate 3 LVAD implantation with diminished surgical trauma, less postoperative bleeding, maintenance of the chest stability, reduced need of blood product transfusion and earlier recovery. Conclusions: The results of our study indicate that less-invasive implantation of the HeartMate 3 is technically feasible and offers several benefits for surgical outcome and may become the standard of care for LVAD implantation techniques.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of thoracic disease

ISSN

2072-1439

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

Supplement 15

Stát vydavatele periodika

CN - Čínská lidová republika

Počet stran výsledku

4

Strana od-do

"S1692"-"S1695"

Kód UT WoS článku

000435843200002

EID výsledku v databázi Scopus

2-s2.0-85048870276